Literature DB >> 7648282

Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals.

F Biron1, F Lucht, D Peyramond, A Fresard, T Vallet, F Nugier, J Grange, S Malley, F Hamedi-Sangsari, J Vila.   

Abstract

HIV is known to be present in massive amounts in both resting and actively replicating cells in infected individuals. We tested the combination of didanosine and hydroxyurea, known to suppress viral production in vitro in both of these cell types, in a small number of asymptomatic patients. After 3 months of well tolerated treatment, we observed a large reduction of viral load in the peripheral blood of all 12 patients, down to nonquantifiable levels in 7 of 12 as measured by infectious virus titer, and 6 of 12 as measured by plasma HIV-RNA. In this subgroup of 6 patients, whose baseline HIV-RNA was below 14,000 copies/ml, the median increase in CD4+ count after 90 days of treatment was 244 cells/mm3.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7648282

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  13 in total

1.  Drug Interactions with Antiretrovirals.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

Review 2.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 3.  Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

Authors:  G J Moyle; B G Gazzard; D A Cooper; J Gatell
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

4.  High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1.

Authors:  T Imamichi; T Sinha; H Imamichi; Y M Zhang; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 5.  Pharmacokinetics and pharmacodynamics of hydroxyurea.

Authors:  P R Gwilt; W G Tracewell
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

6.  Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs.

Authors:  J Neyts; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

7.  Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.

Authors:  S Palmer; R W Shafer; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

8.  An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  D Kern; M Collins; T Fultz; J Detmer; S Hamren; J J Peterkin; P Sheridan; M Urdea; R White; T Yeghiazarian; J Todd
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

9.  Novel inhibitors of human immunodeficiency virus type 2 infectivity.

Authors:  Lauren B Beach; Jonathan M Rawson; Baek Kim; Steven E Patterson; Louis M Mansky
Journal:  J Gen Virol       Date:  2014-08-07       Impact factor: 3.891

Review 10.  Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.

Authors:  Julianna Lisziewicz; Andrea Foli; Mark Wainberg; Franco Lori
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.